


Understanding Fortrea Experience Metrics

Any Questions Contact: Pedro Larco Pedro.Larco@fortrea.com


Fortrea Primary TA Experience:
 5,926 (5,900+) studies
 116k+ sites, 1.08M+ subjects

Fortrea GCD-Only TA Experience:
5,224 Studies, 115k+ sites, >1.08M+ subjects
 Sorted by primary therapeutic area; Each study has only 1 primary therapeutic area

Detailed Therapeutic Area Slides:
 Includes data where study has TA listed as either PRIMARY or SECONDARY TA, so metrics will be fully inclusive and will not exactly match the number on the main TA list.



Global Clinical Experience



Full Year: 2019-2023
 Data source: 5-year data - 2019-2023 Fortrea internal metrics. Data shown represent all studies with Oncology listed as either primary or secondary therapeutic area.
 ***Shown as percentage of all indications. TO BE CHANGED
 ** # of studies conducted per region. Many trials are conducted in multiple regions, some engagements are not region specific and therefore not included in region counts.
 ©2024 Fortrea Inc. All rights reserved. Fortrea.com
 Data reflects Global Commercial Development clinical trial management and functional

Many studies may have a secondary TA. For example, Leukemia may be considered Oncology primary and Hematology Secondary

For internal use only.




Experience Data: Ophthalmology

2019-2023

Fortrea Experience Brought to Your Trial

Presence Across Development Continuum - Trials Running between January 2019 - December 2023



Clin Pharm + Phase I

PHASE I-II

PHASE II

PHASE III

PHASE IV

MULTIPLE¹

DEVICE²

TOTAL

Studies

1,723

196

744

894

461

1,364

544

5,926

Utilized Sites

6,551

3,186

19,002

54,590

7,590

23,081

2,830

116,000+

Participants

64,965

17,596

111,490

618,084

113,816

24,469

130,344

1.080M+

■ CPS + I

■ I-II

■ II III IV

■ Multiple/Not Phase Specific ■ Device and Diagnostic

Source: Internal Company Data. Note: Data includes experience for standalone, full service clinical trial management and functional service provision experiences for phases I-IV, plus clinical pharmacology. Utilized sites are not necessarily unique sites across phases.

¹ Multiple/Not Phase Specific. ² Medical Device & Diagnostic unit.

Fortrea Global Commercial Development Experience Sorted by PRIMARY or SECONDARY Therapeutic Area (2019-2023)

Therapeutic Area	Number of Studies	Number of Sites	Number of Subjects
Bone & Joint Disease	204	4,713	25,000
Cardiovascular	387	9,104	123,511
Dermatology	209	5,627	23,928
Endocrinology and Metabolism	477	8,704	80,521
Gastroenterology	152	5,416	40,662
General Medicine	123	1,350	10,956
Hematology	488	11,058	45,460
Hepatology	251	6,000	45,281
Immunology	498	14,653	84,743
Infectious Disease	307	8,696	364,651
Men's Health	66	3,031	19,525
Multiple	741	1,178	1,056
Nephrology	187	6,350	28,286
Neuroscience	485	6,444	41,125
Oncology	1,364	34,203	266,717
Ophthalmology	113	1,945	12,943
Otolaryngology	74	2,155	10,570
Other	23	16	0
Pain	149	4,361	24,739
Pharmacology	117	167	5,069
Pulmonary/Respiratory	399	14,255	351,241
Reproductive Health	136	6,012	71,551
Rheumatology	95	3,549	18,427
Unspecified	219	20,119	1,378
Urogenital	141	3,662	22,051
Vaccine	128	4,244	277,062
Women's Health	218	9,598	93,560


This data is specific to GCD and does not include CPS data unless included in a GCD-run study.

Source: Internal Company Data 2019-2023. Note: Data includes experience for standalone, full service clinical trial management and functional service provision experiences for phases I-IV, Utilized sites are not necessarily unique sites across phases.

¹ Multiple/Not Phase Specific. ² Medical Device & Diagnostic unit.

Global Commercial Development Experience Brought to Your Trial

Presence Across Development Continuum - Trials Running between January 2019 - December 2023




Data reflects Fortrea Global Commercial Development in-progress trials running between Jan. 2019 – Dec. 2023. It includes experience for standalone, full service clinical trial management and functional service provision experience for Phases I-IV. Does not include 600+ additional CPS studies not using GCD services.

¹ Multiple/Not Phase Specific. ² Medical Device & Diagnostic unit.

Global Commercial Development Experience – Ophthalmology

Studies By Phase




Sites:
1,945


Patients:
12,943

Countries:
46

Study Count Per Region**



Top Indications*



Data source: 5-year data – 2019-2023 Fortrea internal metrics. Data shown represent all studies with Ophthalmology Experience listed as either primary or secondary therapeutic area.

* Shown as percentage of all indications.

** # of studies conducted per region. Many trials are conducted in multiple regions, some engagements are not region specific and therefore not included in region counts.

Data reflects Global Commercial Development in-progress trials running between Jan. 2019 – Dec. 2023. It includes experience for standalone, full service clinical trial management and functional service provision experience for Phases I-IV. Does not include 800+ additional CPS studies not using GCD services.



Thank you